Navigation Links
diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay
Date:3/19/2012

duct.)

** PM Ridker et.al., Clinical Chemistry  58:5 (2012)

About the LIPID trial

The LIPID trial was a randomized controlled trial to determine the effects of cholesterol lowering on death from coronary heart disease among patients with coronary disease and average lipid levels. The trial was designed and initiated by Australian and New Zealand researchers including members of the Clinical Trials Research Unit of Auckland City Hospital, New Zealand. The trial involved 9014 patients, 3,056 of whom were recruited from New Zealand, and all of whom had a prior history of myocardial infarction or hospitalization for unstable angina. The study began in 1990 and was terminated at the end of 1997 (on the advice of the Data Monitoring Committee) as a result of evidence of a clear beneficial effect of pravastatin.

About the JUPITER trial

The JUPITER trial was a randomized, double-blind, placebo-controlled trial that investigated whether rosuvastatin 20 mg compared to placebo would decrease the rate of first major cardiovascular events. The trial enrolled 17,802 apparently healthy men and women with elevated levels of C-reactive protein. The trial was conducted by investigators in 26 countries and overseen by an academic statistician (Robert Glynn, PhD, Harvard University, USA) and an independent Data and Safety Monitoring Board (chaired by Professor Rory Collins, Oxford University, UK). The study was funded by AstraZeneca, US who had no access to unblinded trial data and played no role in analysis or interpretation of the study data or in manuscript preparation. Dr. Ridker, the JUPITER principal investigator, is listed as a co-inventor on patents held by Brigham and Women's Hospital  that relate to the use of inflammatory biomarkers in cardiovascular disease that have been licensed to AstraZeneca.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, is f
'/>"/>

SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
2. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
3. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
4. diaDexus, Inc. Reports 2011 First Quarter Financial Results
5. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
6. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
7. Elekta Highlights Latest Version of MOSAIQ Oncology Information System at HIMSS12 Meeting
8. Bionovo to Host Conference Call to Discuss 2011 Highlights and Year-End Financial Results
9. UBM Medicas Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS
10. Zacks Voice of the People highlights opportunities with Walgreen, Occidental Petroleum and Brown & Brown
11. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... entitled " Lovetraction Lines ." It's for women interested in improving their love ... desire. The course, which officially launched to the public early this morning, has ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association ... and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to ... will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider of ... announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency the ... 24/7 Care At Home’s agency is one of three top Orange County agencies to ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Western ... success of the 2015 Special Olympics World Games, the largest sports and humanitarian event ... the 1984 Olympic Games. , The World Games, held July 25 through August 2, ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... oral cancer, which a dentist could perform by simply using ... set to be developed by researchers at the University of ... The international research team, involving scientists in Sheffield, has been ... to develop the test, which could provide an accurate diagnosis ...
... available in French . Inhibiting prostate cancer ... governs tumour growth A kinase is a type of ... proteins required for cell growth and maintenance, and researchers have ... developing prostate cancer. "It,s known as Mnk, and although it ...
... College of Nursing has been awarded a $753,817 grant ... Health Resources and Services Administration (HRSA), to prepare advanced ... high quality healthcare in rural and medically underserved urban ... to i-LEAD, Innovation in Leadership and Administration in Nursing ...
... Comprehensive Cancer Center and the departments of Chemistry ... uncovered a role for an essential cell protein ... "power plant" of the cell. The import ... for the replication, transcription and translation of the ...
... is twofold, as the patients not only suffer from ... called phantom pain. Unlike bodily wounds which will eventually ... a lifetime. "Phantom pain is very difficult to treat", ... "Mostly they prove to be highly therapy-resistant", the Professor ...
... , THURSDAY, Aug. 5 (HealthDay News) -- While maintaining ... of heart disease and diabetes, being overweight may actually ... researchers say. This new finding suggests that overweight ... open-angle glaucoma (POAG), one of the most common age-related ...
Cached Medicine News:Health News:New 'dentist' test to detect oral cancer will save lives 2Health News:New 'dentist' test to detect oral cancer will save lives 3Health News:Inhibiting prostate cancer without disturbing regular body processes 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 2Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 3Health News:Prosthesis with information at its fingertips 2Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: